Actuate Therapeutics (ACTU) Assets Average (2024 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Assets Average of $15.9 million for Q4 2025, up 34.64% year-over-year from $11.8 million in Q4 2024, and up 28.63% quarter-over-quarter from $12.3 million in Q3 2025.
Actuate Therapeutics (ACTU) Assets Average (2024 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Assets Average for 2 consecutive years, with $15.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average rose 34.64% year-over-year to $15.9 million; the TTM figure through Dec 2025 stood at $15.9 million (up 34.64% YoY), while the FY2025 annual figure was $11.7 million, up 89.66% from the prior year.
- Assets Average advanced to $15.9 million in Q4 2025 per ACTU's latest filing, from $12.3 million in the prior quarter.
- Across five years, Assets Average topped out at $15.9 million in Q4 2025 and bottomed at $5.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | 9.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.87 Mn |
| Sep 30, 2025 | 12.34 Mn |
| Jun 30, 2025 | 5.73 Mn |
| Mar 31, 2025 | 6.90 Mn |
| Dec 31, 2024 | 11.79 Mn |
| Sep 30, 2024 | 8.00 Mn |